a(HBP:cmp16)

Entity

Name

cmp16

Namespace

HBP

Namespace Version

20190222

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/cfd2ee89d1a71126da8b5f452544b7fe43be67e7/export/hbp-names.belns

We next analysed the most prominent Tau aggregation inhibitor compound from a recent- ly published in vitro screen (compound #16 in reference 33), which belongs to the ATPZ class of Tau inhibitors (5-amino-3-(4-chlorophenyl)-N-cyclopropyl-4-oxo-3,4-dihyd- rothieno[3,4- D ]pyridazine-1-carboxamide, referred to as cmp16 for simplicity, structure shown in Fig. 9A). This com- pound prevents Tau fibril formation in vitro, and is able to cross the mammalian blood–brain barrier, an attribute that makes it favourable for clinical applications (33). PubMed:22611162

At 100 m M , we observed improved locomotion of treated animals. These animals moved approximately 1.6 times faster than DMSO-treated controls (Fig. 9A). PubMed:22611162

Treatment with cmp16 diminished the progressive accumulation of neurite gaps in the motor neurons of the pro-aggregant animals compared with the DMSO-treated controls (from 3.2 + 1 gaps at day 5 of the DMSO-treated strains to 2.4 + 1 gaps of the cmp16-treated strains, P , 0.05) (Fig. 9B). Lower accumulation of structural damage in neurons can be interpreted as a sign of reduced neu- rodegeneration (22,58). PubMed:22611162